Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immatics (IMTX)
NASDAQ:IMTX
Immatics (IMTX) Stock Price & Analysis
241 Followers
IMTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.46 - $13.16
Previous Close$10.26
Volume435.88K
Average Volume (3M)452.00K
Market Cap
$1.06B
Enterprise Value$620.82M
Total Cash (Recent Filing)€425.89M
Total Debt (Recent Filing)€15.40M
Price to Earnings (P/E)-7.9
Beta1.03
Next Earnings
May 14, 2024EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding84,657,789
10 Day Avg. Volume313,507
30 Day Avg. Volume452,002
Standard Deviation0.15
R-Squared0.10
Alpha-0.00201
Financial Highlights & Ratios
Price to Book (P/B)3.93
Price to Sales (P/S)16.04
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$17.00Price Target Upside65.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Immatics News
PremiumCompany Announcements
Immatics N.V. Showcases Clinical Strides and Fiscal Health
PremiumPre-Earnings
Is IMTX a Buy, Before Earnings?
PremiumPress Releases
Immatics Announces Proposed Public OfferingBulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe Phase 2/3 study for first generation IMA203 (GEN1) in PRAME+ melanoma is set to initiate, marking a significant step forward in the company's clinical advancement.
InnovationWith a focus on TCR-based therapies, IMTX is at the forefront of developing innovative treatments for solid tumors.
Strategic PartnershipsIMTX sustains strong strategic alliances with high-quality companies, bolstering its position in the biotechnology sector.
Bears Say
Company MilestonesKey events anticipated for the company have now been delayed to the second half of the year.
PartnershipsIts partnership with Genmab was terminated.
Stock PerformanceIMTX shares have underperformed since the last update.
---
Ownership Overview
0.00%
Insiders
8.74% Mutual Funds
0.83% Other Institutional Investors
90.43% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMTX FAQ
What was Immatics’s price range in the past 12 months?
Immatics lowest stock price was $6.46 and its highest was $13.16 in the past 12 months.
What is Immatics’s market cap?
Currently, no data Available
When is Immatics’s upcoming earnings report date?
Immatics’s upcoming earnings report date is May 14, 2024 which is in 19 days.
How were Immatics’s earnings last quarter?
Immatics released its earnings results on Mar 21, 2024. The company reported -$0.331 earnings per share for the quarter, beating the consensus estimate of -$0.341 by $0.011.
Is Immatics overvalued?
According to Wall Street analysts Immatics’s price is currently Undervalued.
Does Immatics pay dividends?
Immatics does not currently pay dividends.
What is Immatics’s EPS estimate?
Immatics’s EPS estimate is -$0.22.
How many shares outstanding does Immatics have?
Immatics has 102,985,070 shares outstanding.
What happened to Immatics’s price movement after its last earnings report?
Immatics reported an EPS of -$0.331 in its last earnings report, beating expectations of -$0.341. Following the earnings report the stock price went down -5.892%.
Which hedge fund is a major shareholder of Immatics?
Among the largest hedge funds holding Immatics’s share is Baker Bros Advisors LP. It holds Immatics’s shares valued at 61M.
---
Immatics Stock Smart Score
Company Description
Immatics
Immatics NV is engaged in discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.
---
IMTX Stock 12 Months Forecast
Average Price Target
$17.00
▲(65.69% Upside)
Technical Analysis
Best Analysts Covering IMTX
1 Year
1 Year Success Rate
7/19 ratings generated profit
1 Year Average Return
-1.61%
reiterated a buy rating 5 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 36.84% of your transactions generating a profit, with an average return of -1.61% per trade.
---